<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53611">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01865331</url>
  </required_header>
  <id_info>
    <org_study_id>NN5401-1788</org_study_id>
    <secondary_id>2006-002615-26</secondary_id>
    <nct_id>NCT01865331</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Single-dose, Parallel Group Trial With Insulin 454 and SIAM 50 in Healthy Male Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate safety,
      tolerability and pharmacokinetic (the exposure of the trial drug in the body) and
      pharmacodynamic (the effect of the investigated drug on the body) characteristics of insulin
      degludec (insulin 454) and insulin degludec/insulin aspart (IDegAsp) 50 - formerly SIAM),
      both explorative formulations, not similar to the proposed commercial formulation, in
      healthy male Japanese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Frequency of adverse events (AEs)</measure>
    <time_frame>From dosing visit and until follow-up 7-21 days after last dosing visit</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum insulin concentration curve</measure>
    <time_frame>0-96 hours after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the glucose infusion rate curve</measure>
    <time_frame>0-24 hours after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Low dose, insulin degludec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose, insulin degludec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose, insulin degludec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IDegAsp 50</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec</intervention_name>
    <description>Single dose administered subcutaneously (s.c., under the skin).</description>
    <arm_group_label>Low dose, insulin degludec</arm_group_label>
    <arm_group_label>Medium dose, insulin degludec</arm_group_label>
    <arm_group_label>High dose, insulin degludec</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin)</description>
    <arm_group_label>Low dose, insulin degludec</arm_group_label>
    <arm_group_label>Medium dose, insulin degludec</arm_group_label>
    <arm_group_label>High dose, insulin degludec</arm_group_label>
    <arm_group_label>IDegAsp 50</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec/insulin aspart 50</intervention_name>
    <description>Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)</description>
    <arm_group_label>IDegAsp 50</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese passport holder

          -  Japanese-born parents

          -  Body mass index (BMI) between 18.0 and 27.0 kg/m^2 (both inclusive)

          -  Fasting blood glucose of below or equal to 6 mmol/L

          -  Healthy male subjects, who are considered to be generally healthy based on an
             assessment of medical history, physical examination and clinical laboratory data at
             screening, as assessment of medical history, physical exjudged by the Investigator

        Exclusion Criteria:

          -  The receipt of any investigational drug within 3 months prior to this trial

          -  Subjects with a history of significant multiple drug allergies or with a known
             allergy to the trialproduct or any medicine chemically related to the trial product,
             as judged by the Investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanne Haahr</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 27, 2013</lastchanged_date>
  <firstreceived_date>May 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin aspart</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
